In a retrospective clinical trial of 50 patients with oligometastatic PCa, including 15 CRPC, Kalinauskaite and others reported that PSMA-based PET-guided radiotherapy could achieve a high 2-year local control rate (96%) while showing fewer side effects (Kalinauskaite et al., 2020). Here, FOLH1 is linked to posterior cortical atrophy.